Emily B. Camire

FDA investigator

Appears on 4 documents from 2023 to 2026, most often at sites in California. Most often cites standard operating procedures (21 CFR 606.100).

4
Documents on file
3.8
Observations per 483
2023
First seen
2026
Most recent

What they cite most

From 15 observations

Activity by year

2023: 1, 2024: 1, 2025: 1, 2026: 1

Where

California 1 · South Korea 1 · Utah 1

Is Emily B. Camire coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

4 documents, newest first
FirmOpen
483 Dendreon Pharmaceuticals LLCMar 25, 2026 · Seal Beach, California
483 Biomat USA, Inc.Jan 9, 2025
483 FDA Form 483 ARUP Laboratories, Inc, Sandy, UT Oct 2024Nov 6, 2024 · Sandy, Utah
483 Form 483 · FEI 3012094568Aug 30, 2023 · Yeonsu, South Korea

About this profile

What does Emily B. Camire inspect?

Emily B. Camire appears on 4 documents on file covering 3 sites, most often in California.

What do they cite most often?

21 CFR 606.100 (standard operating procedures), followed by 21 CFR 1271.270(a) and 21 CFR 606.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Emily B. Camire is dated Mar 25, 2026.